Stefan Knop

Stefan Knop is a Professor in the Department of Internal Medicine V, Division of Oncology and Hematology, affiliated with the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Klinikum Nuernberg. His work focuses on clinical research in multiple myeloma and hematology, including therapeutic strategies, quality of life assessments, and clinical trial design.

His research interests include:

• Multiple Myeloma: Investigating treatment protocols, including novel therapies like daratumumab and carfilzomib, and their efficacy in transplant-ineligible patients.
• Transplantation and Maintenance Therapy: Evaluating alternative regimens and their impact on patient outcomes.
• Minimal Residual Disease (MRD): Developing MRD as a clinical endpoint and its prognostic significance.
• Quality of Life (QoL): Assessing patient-reported outcomes in relapsed/refractory cases and during maintenance therapies.

Recent contributions include a phase 3 trial analyzing daratumumab in multiple myeloma (Lancet Oncology, 2025), a meta-analysis on MRD’s role in clinical trials (Blood, 2024), and studies on QoL in treatment regimens. His work bridges translational research with clinical practice, emphasizing patient-centered outcomes.

No scientific awards are explicitly mentioned in the provided information.

No advising or grant information is available in the provided data.

No specific labs or teams are detailed here, though his work is likely conducted within the Division of Oncology and Hematology at Klinikum Nuernberg.